Huluwa Pharmaceutical Group is a publicly listed company headquartered in Haikou, the capital of Hainan Province, China. As one of the top 20 industrial manufacturers in Hainan Province, Huluwa is committed to driving drug innovation and providing comprehensive health solutions. Huluwa specializes in the R&D, manufacturing, and commercialization of pharmaceutical products across multiple therapeutic areas, including pediatric medications, adult medications, gynecological medications, digestive system medications, and cardiovascular & cerebrovascular medications.

Research Excellence: We have established academician workstations, postdoctoral research stations, and provincial-level innovation platforms.
Extensive Sales Network: Our sales outlets span the entire country, with a dedicated sales team covering over 2,300 counties and cities across China.
Strategic Production Layout: We operate two intelligent production bases in Hainan and Guangxi, boasting a total pharmaceutical production area of 112,944.67 square meters. In addition, we have production bases of raw materials for pharmaceuticals and health products in multiple locations. Our facilities house multiple production lines for raw materials, oral solids, injections, oral dissolving films, and oral solutions, etc.
Diverse Product Portfolio: We currently hold 337 drug approvals, catering to various therapeutic areas such as pediatrics, adults, gynecology, gastrointestinal, cardiovascular & cerebrovascular,and respiratory systems. Current production and sales portfolio includes 111 drugs, including the star products such as the Xiao Er Fei Re Ke Chuan Granules, Chang Yan Ning Granules / Capsules, Azithromycin for Injection, Bromhexine Hydrochloride for Injection, and a range of children’s and adult health supplements.

As one of China’s top 100 pharmaceutical companies, Huluwa Pharmaceutical Group has been recognized as a national-level “Green Factory” and has integrated the ESG principles into our management framework.
Public Welfare Initiatives: We are deeply committed to the education on children’s safe medication practices. Through initiatives like Spring Bud Scholarship, we support girls’ education in remote regions. We actively engage in social welfare programs, establish partnership with the Xuri Dongsheng Charity Foundation on community initiatives, and have maintained nine consecutive years of donations to the Haikou Social Welfare Institute. Total donations to society has exceeded RMB 100 million.